Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

VMD responds to Librela solution concerns
The drug affects fewer than 15 animals for every 10,000 doses sold.
Recent changes to the SPC show additional rare side effects.

The Veterinary Medicines Directorate (VMD) has said that it is ‘constantly reviewing’ Librela Solution for Injection for Dogs, following media reports of adverse events.

The medicinal product, which contains the active substance bedinvetmab, is used for the alleviation of pain caused by osteoarthritis in dogs.

Reports in the media, particularly in the United States of America, throughout 2024 had revealed concerns about adverse effects from the drug. The Food and Drug Administration (FDA) released a statement in December describing severe side effects from the popular drug.

As part of its drug authorisation process, the VMD assesses the safety, quality and efficacy of veterinary medicines before and after authorisation.

Based on findings from recent reports, the VMD updated the Summary of Product Characteristics (SPC) for Librela Solution on 10 December 2024.

The new data reveals that, in rare cases, diarrhoea, emesis, ataxia, urinary incontinence, anorexia and lethargy have been reported. In very rare cases, some dogs have experienced seizures.

Previously recorded adverse events include hypersensitivity reactions, immune-mediated haemolytic anaemia and immune-mediated thrombocytopenia.

The VMD says that any instances of a suspected adverse event are monitored by its pharmacovigilance team. The team assesses reports submitted to the VMD from both veterinary professionals and animal owners.

As with all medicinal products marketed in the UK, the pharmacovigilance team had been continuously monitoring Librela since it was first released in November 2020.

The VMD states that no medicinal product is 100 per cent risk free. It calculates that, according to its data, fewer than 15 animals experience adverse events for every 10,000 doses of Librela sold.

It tells veterinary professionals and pet owners that it is constantly reviewing adverse event report data for authorised medicines. This means that, for each licensed veterinary product, the benefits of the medicine must outweigh the risks posed by potential adverse events.

To report any adverse effects for a drug, find the Marketing Authorisation Holder’s contact details in the product information or find the product on the Product Information Database. Further information about the Librela Solution for Injection in Dogs can be found here.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Applications open for MMI research grants

News Story 1
 RCVS' Mind Matters Initiative (MMI) has launched round two of its veterinary mental health research grants.

Researchers have until 11.59pm on Wednesday, 28 May 2025 to apply for a grant for research which reflects MMI's 2025 focus areas.

Only one Impact Grant was awarded last year, and so this year there are two Discovery Grants and one Impact Grants available. Each Discovery Grant is worth £5,000 and the Impact Grant is worth £15,000.

For more information or to apply, email researchgrants@rcvs.org.uk to contact the MMI team.

 

Click here for more...
News Shorts
Wales licenses Bluetongue vaccines for voluntary use

The Welsh government has approved three Bluetongue vaccines for emergency use in Wales.

From 1 March an online general licence will become available for the vaccines' use. They will then be obtainable on prescription and can be sold by veterinary practices.

After appropriate guidance, livestock keepers will be permitted to administer the vaccines themselves. The vaccines must be prescribed by a veterinary surgeon and detailed vaccination records must be kept for five years.

The decision comes as Bluetongue virus (BTV-3) continues to spread across England. The three vaccines are already licensed for use in England.

Richard Irvine, CVO for Wales, said: "This decision to licence these vaccines was informed by our recent risk assessment indicating that Wales is now at high risk of experiencing an incursion of Bluetongue this year.

"Our primary aim is to keep Bluetongue out of Wales through biosecurity, vigilance and safe sourcing of livestock."